Multiple Sclerosis

Neurological Disorders: Course and Treatment: Second Edition

Volumn , Issue , 2003, Pages 677-706

  Martin, Roland ^a   Hohlfeld, Reinhard ^b   McFarland, H F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547693537     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012125831-3/50248-3     Document Type: Chapter

References (93)

1. Achiron A., Gabbay U., Gilad R., Hassin-Baer S., Barak Y., Gornish M., et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998, 50(2):398-402.
2. Arnon R. The development of Cop1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol. Lett. 1996, 50:1-15.
3. Bandini F., Castello E., Mazzella L., Mancardi G.L., Solaro C. Gabapentin but not vigabitrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis. J. Neurol. Neurosurg. Psychiatry 2001, 71:107-110.
4. Barkhof F., Filippi M., Miller D.H., Scheltens P., Campi A., Polman C.H., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997, 120(Pt 11):2059-2069.
5. Beck R.W., Cleary P.A., Anderson M.M., et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N. Engl. J. Med. 1992, 326:581-588.
6. Beck R.W., Cleary P.A., Trobe J.D., Kaufman D.I., Kupersmith M.J., Paty D.W., et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N. Engl. J. Med. 1993, 329:1764-1769.
7. Becker K.G., Simon R.M., Bailey-Wilson J.E., Freidlin B., Biddison W.E., McFarland H.F., et al. Clustering of nonmajor histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc. Natl. Acad. Sci. USA 1998, 95:9979-9984.
8. Beutler E., Sipe J.C., Romine J.S., Koziol J.A., McMillan R., Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl. Acad. Sci. USA 1996, 93(4):1716-1720.
9. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6:1167-1175.
10. Bornstein M.B., Miller A.I., Slagle S., Weitzman M., Drexler E., Keilson M., et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991, 41:533-539.
11. Burt R.K., Burns W., Ruvolo P., Fischer A., Shiao C., Guimaraes A., et al. Syngeneic bone marrow transplantation eliminates V beta 8.2 T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res. 1995, 41:526-531.
12. Calabresi P.A., Fields N.S., Maloni H.W., Hanham A., Carlino J., Moore J., et al. Phase I trial of transforming growth factor beta 2 in chronic progressive, MS. Neurology 1998, 51:289-298.
13. Coles A.J., Wing M.G., Molyneux P., Paolillo A., Davie C.M., Hale G., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 1999, 46(3):296-304.
14. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., et al. Effect of early interferon treatment on conversion to definite sclerosis: a randomised study. Lancet 2001, 357(9268):1576-1582.
15. Comi G., Filippi M., Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 2001, 49(3):290-297.
16. Confavreux C., et al. Rate of pregnancy-related in multiple sclerosis. N. Engl. J. Med. 1998, 339:285-291.
17. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., Hafler D.A. Glatiramer acetate (Copaxone(R)) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 2000, 105:967-976.
18. Durelli L., Ghezzi A., Montanari E., Zaffaroni M., Bergui E., Verdun E., et al. The independent comparison of interferon (INCOMIN) trial: a multicenter randomized trial comparing clinical and MRI efficacy of IFN beta-1a and beta-1b in multiple sclerosis. Neurology 2001, 56:A148.
19. Edan G., Le Page E., Taurin G., Le Duff F., Kerdoncuff V., De Marco O., et al. Safety profile of mitoxantrone in a cohort of 293 multiple sclerosis patients. Neurology 2001, 56:A149.
20. Edan G., Miller D.H., Clanet M., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicenter, study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry 1997, 62:112-118.
21. Miller D., Polman C., Pozilli C., Thompson A. Interferon beta-1b delays progression of disability in secondary progressive multiple sclerosis: results of a European multicentre randomised trial. Lancet 1998, 352:1491-1497. European Study Group on Interferon-beta 1b in secondary progressive MS.
22. Fassas A., Anagnostopoulos A., Kazis A., Kapinas K., Sakellari I., Kimiskidis V., et al. Autologous stem cell transplantation in progressive multiple sclerosis-an interim analysis of efficacy. J. Clin. Immunol. 2000, 20(1):24-30.
23. Fazekas F., Deisenhammer F., Strasser-Fuchs S., Nahler G., Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997, 349(9052):589-593.
24. Gobbini M.I., Smith M.E., Richert N.D., Frank J.A., McFarland H.F. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J. Neuroimmunol. 1999, 99:142-149.
25. Goodkin D.E., Rudick R.A., VanderBrug Medendorp S., Daughtry M.M., Schwertz K.M., Fischer J., et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 1995, 37:30-40.
26. Gran B., Tranquill L.R., Chen M., Bielekova B., Zhou W., Dhib-Jalbut S., et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000, 55:1704-1714.
27. Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 1988, 2(8604):179-183. Group. British and Dutch Multiple Sclerosis Azathioprine Trial Group.
28. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. Group. The Lenercept Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis GroupThe University of British Columbia MS/MRI Analysis Group.
29. Harris J.O., Frank J.O., Patronas N., McFarlin D.E., McFarland H.F. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implication for clinical trials and natural history. Ann. Neurol. 1991, 29:548-555.
30. Hauser S.L., Dawson D.M., Lehrich J.R., Beal M.F., Kevy S.V., Weiner H.L. Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial. Arch. Neurol. 1983, 40(11):687-690.
31. Hohlfeld R. Neurological autoimmune disease and the trimolecular complex of T lymphocytes. Ann. Neurol. 1989, 25:531-538.
32. Hohlfeld R. Biotechnological agents of the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997, 120:865-916.
33. Hughes R.A.C. Treatment of multiple sclerosis with azathioprine. Treatment of Multiple Sclerosis 1992, 157-172. Springer, London. R.A. Rudick, D.E. Goodkin (Eds.).
34. Jacobs L., Salazar A.M., Herndon R. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis: results of a multicenter double-blind study. Arch. Neurol. 1987, 44:589-595.
35. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.F., Brownscheidle C.M., Murray T.J., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000, 343:898-904.
36. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in multiple sclerosis. Ann. Neurol. 1996, 39:285-294.
37. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase-III multicenter, double-blind, placebo-controlled trial. Neurology 1995, 45:1268-1276.
38. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998, 50:701-708.
39. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., et al. Induction of a non-encephalitogenic type 2 T helpercell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat. Med. 2000, 6:1176-1182.
40. Kappos L., Patzold U., Dommasch D., Poser S., Haas J., Krauseneck P., et al. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis-results of the German multicenter study. Ann. Neurol. 1988, 23(1):56-63.
41. Kesselring J. Multiple Sklerose 1992, Kohlhammer, Stuttgart.
42. Khatri B.O., McQuillen M.P., Harrington G.J., Schmoll D., Hoffmann R.G. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985, 35(3):312-319.
43. Kojima K., Berger T., Lassmann H., Hinze-Selch D., Zhang Y., Gehrmann J., et al. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100b molecule, a calcium binding protein of astroglia. J. Exp. Med. 1994, 180:817-829.
44. Kümpfel T., Schumann E., Then Bergh F., Gottschalk M., Auer D., Holsboer F., et al. Monthly high-dose methylprednisolone pulse therapy in patients with multiple sclerosis: an MRI controlled study with single crossover design. Neurology 2001, 56:A76.
45. Lublin F., Cutter G., Elfont R., Khan O., Lisak R., McFarland H.F., et al. A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate inpatients with relapsing, MS. Neurology 2001, 56:A148.
46. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
47. Mackin G.A., Dawson D.M., Hafler D.A., Weiner H.L. Treatment of multiple sclerosis with cyclophosphamide. Treatment of Multiple Sclerosis 1992, 199-216. Springer, London. R.A. Rudick, D.E. Goodkin (Eds.).
48. Madsen L.S., Andersson E.C., Jansson L., Krogsgaard M., Engberg J., et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 1999, 23:343-347.
49. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992, 10:153-187.
50. Mauch E., Kornhuber H.H., Krapf H., Fetzer U., Laufen H. Treatment of multiple sclerosis with mitoxantrone. Eur. Arch. Psychiatry Clin. Neurosci. 1992, 242(2-3):96-102.
51. McDonald W.I., Compston D.A.S., Edan G., Goodkin D.E., Hartung H.P., Lublin F.D., et al. Diagnostic criteria for MS: guidelines from the International Panel on the Diagnosis of MS. Ann. Neurol. 2001, 50:121-127.
52. McFarland H.F., Barkhof F., Antel J., Miller D.H. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult. Scler. 2002, 8:40-51.
53. McFarlin D.E., McFarland H.F. Multiple sclerosis, (Part 1). N. Engl. J. Med. 1982, 307:1183-1188.
54. McFarlin D.E., McFarland H.F. Multiple sclerosis (Part 2). N. Engl. J. Med. 1982, 307:1246-1251.
55. Milanese C., La Mantia L., Salmaggi A., Caputo D. Azathioprine and interferon beta-1b treatment in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2001, 70(3):413-414.
56. Miller D.H., Thompson A.J., Morissey S.P., MacManus D.G., Moore S.G., Kendall B.E., et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanisms of therapeutic effects. J. Neurol. Neurosurg. Psychiatry 1992, 55:450-453.
57. Molyneux P.D., Kappos L., Polman C., Pozzilli C., Barkhof F., Filippi M., et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000, 123(Pt 11):2256-2263.
58. Morissey S.P., Miller D.H., Kendall B.E., Kingsley D.P.E., Kelly M.A., Francis D.A., et al. The significance of resonance imaging abnormalities at presentation, with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993, 116:135-146.
59. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis. A randomized, double-blind, placebo-controlled clinical trial. Ann. Neurol. 1990, 27:591-605. MSS Group.
60. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Then Bergh F., Dose T., et al. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. USA 2000, 97:7452-7457.
61. Noseworthy J.H., Luccinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
62. Noseworthy J.H., Vandervoort M.K., Penman M., Ebers G., Shumak K., Seland T.P., et al. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 1991, 337(8756):1540-1541.
63. Panitch H.S., Hirsch R.L., Schindler J., Johnson K.P. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 1987, 37:1097-1102.
64. Paty D.W., Li D.K.B. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:662-667. UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group.
65. Paty D.W., McFarland H.F. Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis and to monitor definitive clinical trials. J. Neurol. Neurosurg. Psychiatry 1998, 64:S47-S51.
66. Petajan J.H., Gappmaier E., White A.T., Spencer M.K., Mino L., Hicks R.W. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann. Neurol. 1996, 39:432-441.
67. Poser C.M., Paty D.W., Scheinberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
68. PRISMS-4 Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001, 56:1628-1636.
69. Prineas J.W. The neuropathology of multiple sclerosis. Handbook of Clinical Neurology, Demyelinating Diseases 1985, 213-257. Elsevier Scian, Amsterdam/New York. P.J. Vinken, G.W. Bruyn, H.L. Klawans, J.C. Koetsier (Eds.).
70. Reder A.T., Arnason B.G.W. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology 1995, 45:1097-1100.
71. Rohrbach E., Kappos L., Städt D., Kaiser D., Hennes A., Dommasch D., et al. Intrathecal versus oral corticosteroid therapy of spinal symptoms in multiple sclerosis: a double-blind controlled trial. Neurology 1988, 38(Suppl. 1):256.
72. Romine J.S., Sipe J.C., Koziol J.A., Zyroff J., Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians 1999, 111(1):35-44.
73. Rudge P., Koetsier J.C., Mertin J., Mispelblom Beyer J.O., Van Walbeek H.K., Clifford Jones R., et al. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1989, 52(5):559-565.
74. Sipe J.C., Romine J.S., Koziol J.A., McMillan R., Zyroff J., Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994, 344:9-13.
75. Smith M.E., Stone L.A., Albert P.S., et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadolinium enhancing MRI lesions. Ann. Neurol. 1993, 33:480-489.
76. Stone L.A., Frank J.A., Albert P.S., Bash C., Smith M.E., Maloni H., et al. The effect of interferon-b on blood-brain-barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol. 1995, 37:611-619.
77. Stone L.A., Smith M.E., Albert P.S., Bash C.N., Maloni H., Frank J.A., et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology 1995, 45:1122-1126.
78. Tan I.L., Lycklama A, Nijeholt G.J., Polman C.H., Ader H.J., Barkhof F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult. Scler. 2000, 6(2):99-104.
79. Teitelbaum D., Milo R., Arnon R., Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc. Natl. Acad. Sci. USA 1992, 89:137-141.
80. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661. The Interferon-B Multiple Sclerosis Study Group.
81. Tintore M., Rovira A., Martinez M.J., Rio J., Diaz-Villoslada P., Brieva L., et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. A.J.N.R. Am. J. Neuroradiol. 2000, 21(4):702-706.
82. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R.M., Moerk S., Boe L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
83. Tubridy N., Behan P.O., Capildeo R., Chaudhuri A., Forbes R., Hawkins C.P., et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in, MS The UK Antegren Study Group. Neurology 1999, 53(3):466-472.
84. Tumani H., Tourtellotte W.W., Peter J.B., Felgenhauer K. Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. The Optic Neuritis Study Group. J. Neurol. Sci. 1998, 155(1):44-49.
85. van Diemen H.A., Poman C.H., van Dongen T.M., van Loenen A.C., Nauta J.J., Taphoorn M.J., van Walbeek H.K., Koetsier J.C. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, cross-over study. Ann. Neurol. 1992, 32:123-130.
86. van Diemen H.A.M., Polman C.H., van Dongen M.M.M.M., Nauta J.J.P., Strijers R.L.M., Loenen A.C., et al. 4-aminopyridine induces functional improvement in multiple sclerosis: a neurophysiological study. J. Neurol. Sci. 1993, 116:220-226.
87. van Oosten B.W., Barkhof F., Truyen L., Baringa J.B., Bertelsmann F.W., van Blomberg B.M., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996, 47:1531-1534.
88. Wandinger K.P., Stürzebecher C.-S., Bielekova B., Detore G., Rosenwald A., Staudt L.M., McFarland H.F., Martin R. The complex immunomodulatory effects of interferon-b in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 2001, 50:349-357.
89. Weiner H.L., Dau P.C., Khatri B.O., Petajan J., Birnbaum G., McQuillen M.P., et al. Double-blin study of true, vs. sham plasmapheresis in patients being treated with immunosuppression for acute attacks of multiple sclerosis. Prog. Clin. Biol. Res. 1990, 337(283):283.
90. Weiner H.L., Mackin G.A., Orav E.J., Hafler D.A., Dawson D.M., LaPierre Y., et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993, 43:910-918.
91. Weinshenker B.G. Natural history of multiple sclerosis. Ann. Neurol. 1994, 36:S6-S11.
92. Wiles C.M., Omar L., Swan A.V., Sawle G., Frankel J., Grunewald R., et al. Total lymphoid irradiation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1994, 57(2):154-163.
93. Yudkin P.L., Ellison G.W., Ghezzi A., Goodkin D.E., Hughes R.A.C., McPherson K., et al. Overview of azathioprine in multiple sclerosis. Lancet 1991, 338:1051-1055.